Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.47 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PHGDH | O43175 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532062 | 0.90 | NR3C2 (0.61) | HPGDPOLBNR3C2CNR1PKM | |
| SCHEMBL14072995 | 0.88 | HPGD (0.57) | HPGDNR3C2CNR1PKML3MBTL1 | |
| SCHEMBL14073003 | 0.86 | HPGD (0.57) | HPGDPOLBNR3C2KMT2ALMNA | |
| SCHEMBL6214174 | 0.79 | POLB (0.53) | HPGDPOLBPKMDNMT1PTPN7 | |
| SCHEMBL7325238 | 0.78 | CRBN (0.58) | HPGDPOLBPKMDNMT1PTPN7 | |
| SCHEMBL14072961 | 0.78 | NR3C2 (0.61) | HPGDNR3C2PKMLMNATSHR | |
| SCHEMBL941445 | 0.78 | GAA (0.56) | NR3C2PKMKMT2ALMNAALDH1A1 | |
| SCHEMBL6780554 | 0.78 | HPGD (0.52) | HPGDPOLBCNR1PKMDNMT1 | |
| SCHEMBL3283784 | 0.76 | ALDH1A1 (0.56) | POLBPKMLMNATSHRALDH1A1 | |
| SCHEMBL7349545 | 0.76 | ALDH1A1 (0.52) | POLBPKMLMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| EP-1359917-B1 | THIOXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN CO LLC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-6821969-B2 | FOR THERAPY AND PROPHYLAXIS OF HERPESVIRAL INFECTION | PHARMACIA & UPJOHN COMPANY | 2004-11-23 | — | — | US | disclosed |
| EP-1359917-A1 | THIOXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-12 | — | — | EP | disclosed |
| EP-1220858-B1 | OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | UPJOHN CO (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20020143013-A1 | Thioxazinoquinolones as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-10-03 | — | — | US | disclosed |
| WO-2002064145-A1 | THIOXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2002-08-22 | — | — | WO | disclosed |
| EP-1220858-A2 | OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2002-07-10 | — | — | EP | disclosed |
| US-6340680-B1 | AS ANTIVIRAL AGENTS, AGAINST VIRUSES OF HERPES FAMILY | PHARMACIA AND UPJOHN COMPANY | 2002-01-22 | — | — | US | disclosed |
| WO-2001025239-A2 | OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP12, MMP13, MMP25 | HPGD 89/4885POLB 2906/4885NR3C2 2939/4885 |
| US-20020143013-A1 | Thioxazinoquinolones as antiviral agents | DDX5, IRF3, ZC3HAV1 | HPGD 1954/4885POLB 1044/4885NR3C2 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.